Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Study of INCB099280 in Combination With Ipilimumab in Participants With Select Solid Tumors

NCT05909995 is registered in ClinicalTrials.gov with Incyte Corporation as lead sponsor.

NCT NCT05909995
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05909995 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Study of INCB099280 in Combination With Ipilimumab in Participants With Select Solid Tumors
Lead sponsor
Incyte Corporation
Phase
Phase 1
Overall status
Terminated
Start date
August 29, 2023
Completion date
November 11, 2024
Enrollment
8 (actual)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

colorectal carcinoma (crc), hepatocellular carcinoma (hcc), melanoma, microsatellite instability - high (msi-h), mismatch repair deficient (dmmr), renal cell carcinoma (rcc)